(Total Views: 298)
Posted On: 10/10/2017 8:15:39 AM
Post# of 40989
CBIS,,,Another company mentioned,,,announced a couple weeks ago they will increase the number of shares to 12,000,000,000 - price (of course has dropped significantly) -- and we thought ONCI was share heavy.
The mainstream pharmaceutical industry is capital-intensive and constrained by high regulatory hurdles, making the profitability of any particular product a long-term prospect. Cannabis Science™ is different in three key respects:
The Company will, at least in its first phase of existence, deal primarily in intellectual properties "patents on products and processes" leaving capital-intensive problems such as regulatory compliance, mass production and marketing to the "old guard" pharmaceutical companies who license our patents.
We will focus on a relatively new and under-explored niche in the pharmaceutical market: Whole-plant cannabinoid compounds derived from certified organic ingredients. The existing pharmaceutical industry is heavily geared, by inclination and in terms of infrastructure, toward the development and testing of synthetic compounds.
Cannabis Science™ has strong roots in, and an established relationship of trust with, the US and Canadian medical cannabis patient communities. In the course of product and process development, we'll do "well" by doing "good" - our products will receive baseline efficacy testing in that community. Since medical cannabis already inherently exceeds all reasonable standards of safety, potential licensees will approach the regulatory process with a reasonable expectation that the products and processes they license will easily exceed that process's safety and efficacy standards. Thus our products and processes will enjoy a significant advantage over previously untested synthetics.
The mainstream pharmaceutical industry is capital-intensive and constrained by high regulatory hurdles, making the profitability of any particular product a long-term prospect. Cannabis Science™ is different in three key respects:
The Company will, at least in its first phase of existence, deal primarily in intellectual properties "patents on products and processes" leaving capital-intensive problems such as regulatory compliance, mass production and marketing to the "old guard" pharmaceutical companies who license our patents.
We will focus on a relatively new and under-explored niche in the pharmaceutical market: Whole-plant cannabinoid compounds derived from certified organic ingredients. The existing pharmaceutical industry is heavily geared, by inclination and in terms of infrastructure, toward the development and testing of synthetic compounds.
Cannabis Science™ has strong roots in, and an established relationship of trust with, the US and Canadian medical cannabis patient communities. In the course of product and process development, we'll do "well" by doing "good" - our products will receive baseline efficacy testing in that community. Since medical cannabis already inherently exceeds all reasonable standards of safety, potential licensees will approach the regulatory process with a reasonable expectation that the products and processes they license will easily exceed that process's safety and efficacy standards. Thus our products and processes will enjoy a significant advantage over previously untested synthetics.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280